Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 31, 2007

OGT and Sanger Institute Work on a Test for Prenatal Syndromes

  • Oxford Gene Technology (OGT) and the Wellcome Trust Sanger Institute will develop a single-platform microarray to test for genetic defects in unborn children. The goal of is to develop and validate a microarray to specifically target a number of key prenatal syndromes.

    OGT will design and develop the  60-mer oligonucleotide microarray using its ink jet in situ synthesis platform and work. The company will work with the Sanger Institute’s clinical network to target the most appropriate syndromes.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.